A study to evaluate psoriasis outcomes and safety events in patients with chronic moderate to severe plaque psoriasis

Journal of Drugs in Dermatology, Nov, 2007

Sponsored by Genentech. This is a multicenter, prospective, 5-year surveillance study of approximately 5,000 Raptiva[R]-treated patients and approximately 500 non-Raptiva treated patients (formerly 2,500 comparison patients who were treated with a biologic therapy other than Raptiva) with chronic moderate to severe plaque psoriasis who are candidates for treatment with Raptiva.

Condition

Psoriasis

Study ID Numbers: ACD3101g

ClinicalTrials.gov Identifier: NCT00096928